264 related articles for article (PubMed ID: 33614888)
1. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.
Matthews DC; Ritter A; Thomas RG; Andrews RD; Lukic AS; Revta C; Kinney JW; Tousi B; Leverenz JB; Fillit H; Zhong K; Feldman HH; Cummings J
Alzheimers Dement (N Y); 2021; 7(1):e12106. PubMed ID: 33614888
[TBL] [Abstract][Full Text] [Related]
2. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
3. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
[TBL] [Abstract][Full Text] [Related]
4. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
5. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease.
Matthews DC; Mao X; Dowd K; Tsakanikas D; Jiang CS; Meuser C; Andrews RD; Lukic AS; Lee J; Hampilos N; Shafiian N; Sano M; David Mozley P; Fillit H; McEwen BS; Shungu DC; Pereira AC
Brain; 2021 Dec; 144(12):3742-3755. PubMed ID: 34145880
[TBL] [Abstract][Full Text] [Related]
6. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
7. Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Zimmer JA; Shcherbinin S; Devous MD; Bragg SM; Selzler KJ; Wessels AM; Shering C; Mullen J; Landry J; Andersen SW; Downing AM; Fleisher AS; Svaldi DO; Sims JR
Alzheimers Dement (N Y); 2021; 7(1):e12123. PubMed ID: 33614894
[TBL] [Abstract][Full Text] [Related]
8. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
9. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
[TBL] [Abstract][Full Text] [Related]
10. Latrepirdine for Alzheimer's disease.
Chau S; Herrmann N; Ruthirakuhan MT; Chen JJ; Lanctôt KL
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009524. PubMed ID: 25897825
[TBL] [Abstract][Full Text] [Related]
11. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
12. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative.
Premnath PY; Locascio JJ; Mimmack KJ; Gonzalez C; Properzi MJ; Udeogu O; Rosenberg PB; Marshall GA; Gatchel JR;
Alzheimers Dement (N Y); 2024; 10(1):e12442. PubMed ID: 38356477
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
15. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
[TBL] [Abstract][Full Text] [Related]
16. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
Henderson ST; Vogel JL; Barr LJ; Garvin F; Jones JJ; Costantini LC
Nutr Metab (Lond); 2009 Aug; 6():31. PubMed ID: 19664276
[TBL] [Abstract][Full Text] [Related]
17. Galantamine for Alzheimer's disease and mild cognitive impairment.
Loy C; Schneider L
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]